QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:ONCS

OncoSec Medical (ONCS) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.20
▼
$0.94
52-Week Range
N/A
Volume
52.49 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

ONCS stock logo

About OncoSec Medical (NASDAQ:ONCS) Stock

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.


ONCS Stock News Headlines

June 24, 2023 | finance.yahoo.com
ONCS - OncoSec Medical Incorporated
June 23, 2023 | markets.businessinsider.com
Why Is OncoSec Medical (ONCS) Stock Up 100% Today?
September 28, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
June 15, 2023 | msn.com
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 15, 2023 | msn.com
Why Is OncoSec Medical (ONCS) Stock Down 48% Today?
May 18, 2023 | finance.yahoo.com
OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
May 16, 2023 | msn.com
OncoSec Medical plunges 35% lower on sale of 1.4M shares of common stock
May 16, 2023 | finance.yahoo.com
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
September 28, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
May 16, 2023 | finance.yahoo.com
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
April 27, 2023 | finance.yahoo.com
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
April 11, 2023 | finance.yahoo.com
OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 10, 2023 | msn.com
Why OncoSec Medical Shares Are Soaring Today
April 10, 2023 | finance.yahoo.com
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 6, 2023 | benzinga.com
OncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Trading
April 3, 2023 | finance.yahoo.com
OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study
April 3, 2023 | msn.com
OncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trial
April 3, 2023 | finance.yahoo.com
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
March 1, 2023 | marketwatch.com
OncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%
March 1, 2023 | msn.com
Why is OncoSec Medical (ONCS) Stock Up 91% Today?
January 16, 2023 | reuters.com
ONCS.OQ - | Stock Price & Latest News | Reuters
January 5, 2023 | benzinga.com
OncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summary
December 8, 2022 | msn.com
Peering Into OncoSec Medical's Recent Short Interest
December 5, 2022 | finance.yahoo.com
OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022
November 30, 2022 | marketwatch.com
OncoSec Shares Drop 25% on Equity Offer Pricing After 51% Tuesday Surge
November 30, 2022 | finance.yahoo.com
OncoSec Announces Pricing of $3.5 Million Public Offering
November 24, 2022 | finance.yahoo.com
OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer
See More Headlines
Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

ONCS Company Calendar

Last Earnings
12/14/2021
Today
9/28/2023
Fiscal Year End
7/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCS
CUSIP
N/A
CIK
1444307
Web
www.oncosec.com
Phone
(855) 662-6732
Fax
858-430-3832
Employees
40
Year Founded
2011

Profitability

EPS (Most Recent Fiscal Year)
($15.2865)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-34,180,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-868.29%
Return on Assets
-160.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.89
Quick Ratio
0.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.42 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,550,000
Free Float
4,494,000
Market Cap
$1.26 million
Optionable
Not Optionable
Beta
1.99

Social Links

10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Robert H. Arch
    President, CEO & Non-Independent Director
  • George Chi
    Chief Financial Officer
  • David Canton
    Vice President-Research & Development
  • Sandra Aung
    Chief Clinical Development Officer & Senior VP
  • Bridget O'Keeffe
    Vice President-Clinical Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













ONCS Stock - Frequently Asked Questions

Should I buy or sell OncoSec Medical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ONCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCS, but not buy additional shares or sell existing shares.
View ONCS analyst ratings or view top-rated stocks.

How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) issued its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) EPS for the quarter, topping analysts' consensus estimates of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

OncoSec Medical shares reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

What is OncoSec Medical's stock symbol?

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

How much money does OncoSec Medical make?

OncoSec Medical (NASDAQ:ONCS) has a market capitalization of $0.00. The biotechnology company earns $-34,180,000.00 in net income (profit) each year or ($15.2865) on an earnings per share basis.

How can I contact OncoSec Medical?

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The official website for the company is www.oncosec.com. The biotechnology company can be reached via phone at (855) 662-6732, via email at investors@oncosec.com, or via fax at 858-430-3832.

This page (NASDAQ:ONCS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -